EXACT Sciences Corporation (EXAS)

EXACT Sciences Corporation (EXAS) is a Diagnostics & Research company in the Healthcare sector listed on the NASDAQ.

As of Apr 17, 2026: market cap $20B; returns 1 week -0.5%.

Exact Sciences Corporation is a premier molecular diagnostics company specialized in the early detection and prevention of cancer. Its business model is built on two primary pillars: Screening and Precision Oncology. The Screening segment, which accounts for approximately 75-80% of total revenue, is dominated by Cologuard, a non-invasive, stool-based DNA screening test for colorectal cancer.

EXAS financial model: income statement, cash flow and balance sheet